Lexagene Holdings (Lexagene Holdings) Cash And Cash Equivalents : $0.46 Mil (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Cash And Cash Equivalents?

Lexagene Holdings's quarterly cash and cash equivalents declined from May. 2022 ($2.82 Mil) to Aug. 2022 ($1.09 Mil) but then stayed the same from Aug. 2022 ($1.09 Mil) to Nov. 2022 ($0.46 Mil).

Lexagene Holdings's annual cash and cash equivalents increased from Feb. 2020 ($3.19 Mil) to Feb. 2021 ($9.62 Mil) but then declined from Feb. 2021 ($9.62 Mil) to Feb. 2022 ($4.72 Mil).

Lexagene Holdings Cash And Cash Equivalents Historical Data

The historical data trend for Lexagene Holdings's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Cash And Cash Equivalents Chart

Lexagene Holdings Annual Data

Trend

Mar13

Mar14

Mar15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Cash And Cash Equivalents

Get a 7-Day Free Trial

2.65

0.67

3.19

9.62

4.72

Lexagene Holdings Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Cash And Cash Equivalents	Get a 7-Day Free Trial															1.72	4.72	2.82	1.09	0.46

Lexagene Holdings Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Lexagene Holdings (OTCPK:LXXGQ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Lexagene Holdings Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexagene Holdings (Lexagene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915

Website

https://www.lexagene.com

Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.